Retrospective study on the impact of hepatitis B and hepatitis C virus infection on hematopoietic stem cell transplantation in Japan

International Journal of Hematology

Volumn 75, Issue 3, 2002, Pages 324-331

  Hamaguchi, Motohiro ^a,f   Yamad, Hironori ^a   Gondo, Hisashi ^b   Takemoto, Yoshinobu ^c   Morishima, Yasuo ^d   Kodera, Yoshihisa ^e  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Department of Hematology   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^f NONE   (Japan)

Author keywords

HBV; HCV; Hepatic failure; Hepatitis; Stem cell transplant

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CONTROLLED STUDY; DONOR; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; VEIN OCCLUSION; VIRUS REACTIVATION; ADOLESCENT; ADULT; APLASTIC ANEMIA; CHILD; CLINICAL TRIAL; FEMALE; INFANT; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMANS; INFANT; JAPAN; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES;

EID: 0036548589     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982051     Document Type: Article

References (20)

1. Lau GKK, Liang R, Chiu EKW, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997;19:795-799.
2. Ustun C, Koc H, Karayalcin S, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:289-296.
3. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood. 1999;93:1127-1136.
4. Chen YC, Lin KH, Huang WS, Tang JL. Bone marrow transplantation in Taiwan: an overview. Bone Marrow Transplant. 1994;13:705-708.
5. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation. Transplantation. 1998;66:616-619.
6. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83:1998-2004.
7. Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood. 1991;77:195-200.
8. Rodriguez-Inigo E, Thomas JF, Gomez-Garcia de Soria V, et al. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study. Blood. 1997;90:1326-1331.
9. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European group for blood and marrow transplantation. Blood. 1998;92:3599-3604.
10. Locasciulli A, Testa M, Valsecchi MG. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation. 1999;68:1486-1491.
11. Locasciulli A, Bacigalupo A, Van Lint MT, et al. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases. Bone Marrow Transplant. 1990;6:25-29.
12. + donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 1995;86:3236-3240.
13. Lau GKK, Lie A, Kwong YL, et al. A case-controlled study on the use of HbsAg(+) donors for allogeneic hematopoietic cell transplantation. Blood. 2000;96:452-458.
14. Ustun C, Idilman R, Gurman G, et al. Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe. J Hepatol. 1999;31:202-209.
15. Fan FS, Tzeng CH, Yeh HM, et al. Reverse seroconversion of hepatitis B virus infectious status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant. 1991;8:417-420.
16. Webster A, Brenner MK, Prentice HG, et al. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989;4:207-213.
17. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation. 1990;49:708-713.
18. Lai CL, Chien RN, Leung N, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-68.
19. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
20. Locasciulli A, Alberti A. Hepatitis B and hepatitis C virus infections in stem cell transplantation. Leuk Lymphoma. 1999;35:255-260.